Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Andrew Berens has given his Buy rating due to a combination of factors, primarily focusing on AstraZeneca’s solid financial performance and optimistic future guidance. The company reported a total product revenue that exceeded consensus expectations, driven by strong performances in its oncology division and other key products. Despite some products missing consensus expectations, the overall results were positive, with a slight beat in core EPS.
Additionally, AstraZeneca’s guidance for 2025 reflects confidence in continued revenue and EPS growth, suggesting a promising outlook. While there are ongoing concerns related to a tax issue in China, the potential fines appear to be lower than initially feared. Furthermore, the upcoming Phase 3 readouts for several new therapies are expected to bolster revenues significantly by 2030, reinforcing the Buy rating.
In another report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $88.00 price target.